List of Excipients in Branded Drug LIPOFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	LIPOFEN	fenofibrate	62559-305	D&C YELLOW NO. 10
ANI Pharmaceuticals Inc	LIPOFEN	fenofibrate	62559-305	FD&C BLUE NO. 1
ANI Pharmaceuticals Inc	LIPOFEN	fenofibrate	62559-305	FD&C BLUE NO. 2

Lipofen Excipient Strategy and Commercial Opportunities for Fenofibrate Capsules

Last updated: August 24, 2026

Lipofen is an oral fenofibrate product marketed in 50 mg and 150 mg capsules for hypertriglyceridemia and mixed dyslipidemia. Its commercial protection is driven less by active-ingredient patents than by generic pricing, bioequivalence execution, formulation differentiation, manufacturing efficiency, and access to regulated markets. The strongest excipient opportunities are low-risk improvements to dissolution consistency, food-effect performance, capsule robustness, stability, and patient usability.

What is Lipofen and how is it formulated?

Lipofen contains fenofibrate, a fibric acid derivative that lowers triglycerides and can increase high-density lipoprotein cholesterol. The product is administered orally and is available in 50 mg and 150 mg capsule strengths. The FDA-approved labeling identifies Lipofen as a capsule formulation containing micronized fenofibrate or a comparable finely divided drug substance designed to improve oral absorption relative to coarse fenofibrate material (U.S. Food and Drug Administration [FDA], 2018).

Lipofen product profile

Attribute	Lipofen profile
Active ingredient	Fenofibrate
Dosage form	Oral capsule
Strengths	50 mg and 150 mg
Therapeutic class	Fibric acid derivative
Primary indications	Severe hypertriglyceridemia; primary hypercholesterolemia or mixed dyslipidemia
Sponsor/manufacturer	Kowa Pharmaceuticals America, Inc.
FDA pathway	505(b)(1) NDA product
Generic competition	Established
Biosimilar relevance	None; fenofibrate is a small molecule
Main development risk	Bioequivalence, dissolution, food-effect performance, and commercial cost

Fenofibrate has low and variable aqueous solubility. Particle-size control and formulation design affect dissolution and systemic exposure. The excipient system therefore has a direct relationship with regulatory performance, even though the excipients themselves are generally conventional.

What excipients are relevant to Lipofen development?

The commercial label and product-specific regulatory records should control any exact comparison of Lipofen’s inactive ingredients. For competitive development, the relevant excipient classes are more important than the brand’s precise qualitative formula.

Core excipient functions

Excipient or material class	Function in a fenofibrate capsule	Commercial relevance
Lactose or other water-soluble diluent	Provides fill mass and supports wetting	Low cost, broad supplier base, possible lactose-intolerance and compatibility considerations
Starch or modified starch	Diluent, disintegrant, or carrier	Supports capsule breakup and manufacturing throughput
Crospovidone or croscarmellose sodium	Superdisintegrant	Can improve dispersion of hydrophobic fenofibrate
Povidone or copovidone	Binder and wetting aid	Useful in granulation or carrier-based dispersion systems
Sodium lauryl sulfate or similar surfactant	Improves wetting of hydrophobic drug particles	May improve dissolution but requires tight control of level and impurity profile
Magnesium stearate	Lubricant	Necessary for capsule-filling performance, but excess levels can slow dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and fill-weight consistency
Talc	Glidant or processing aid	May improve flow but requires control of inhalation and elemental impurity concerns
Gelatin or HPMC capsule shell	Encloses the powder or granules	HPMC supports vegetarian, lower-moisture, and certain stability-positioning strategies
Titanium dioxide and approved colorants	Capsule identification and appearance	Supports product differentiation and strength recognition

The key formulation tension is between powder-flow performance and dissolution. Hydrophobic fenofibrate can require surfactant, micronization, porous carriers, granulation, or solid-dispersion technology. Heavy lubrication, excessive hydrophobic coating, or poor powder deagglomeration can reduce dissolution and create batch-to-batch variability.

What excipient strategies can improve Lipofen performance?

The most practical strategies fall into four categories: conventional capsule optimization, lipid-based delivery, solid dispersion, and particle-engineered formulations.

Conventional powder-fill optimization

A generic or line-extension product can use micronized fenofibrate with a carrier-disintegrant system. A typical development program would screen:

1. Drug-particle size and particle-size distribution.
2. Diluent-to-drug ratio.
3. Superdisintegrant concentration.
4. Surfactant concentration.
5. Lubrication time and magnesium stearate level.
6. Capsule shell moisture and dissolution behavior.
7. Fill-weight uniformity and powder-flow properties.

This route generally has the lowest regulatory and manufacturing risk. It is suitable for an ANDA if the product can meet the relevant pharmaceutical equivalence and bioequivalence requirements.

The main weakness is limited differentiation. A conventional capsule can compete on price and supply reliability, but the product may have little protection beyond manufacturing know-how, trademarks, and any newly generated formulation or process rights.

Lipid-based excipient systems

Lipid-based systems can improve solubilization of fenofibrate and reduce dependence on drug micronization. Candidate systems include medium-chain triglycerides, long-chain glycerides, surfactants, cosolvents, and self-emulsifying delivery systems.

A lipid-based fenofibrate capsule could offer:

• More reproducible drug dispersion.
• Potentially improved dissolution under low-bile or fasted conditions.
• A differentiated food-effect profile.
• Reduced dependence on very fine drug-particle size.

The main risks are physical instability, capsule-shell interaction, fill leakage, oxidation, precipitation after dilution, and more complex manufacturing controls. A lipid formulation also may not be interchangeable with a conventional product without a full bioequivalence assessment.

Amorphous solid dispersions

Amorphous solid dispersions using polymers such as copovidone, hypromellose acetate succinate, or similar carriers can increase apparent solubility and maintain fenofibrate in a supersaturated state during dissolution.

The development value is highest when the sponsor can demonstrate:

• Improved dissolution across physiologically relevant media.
• Reduced food-effect variability.
• Physical stability through the proposed shelf life.
• Reproducible amorphous content.
• Acceptable capsule fill mass.
• No unacceptable polymer-related gastrointestinal effects.

The primary risk is recrystallization. A solid dispersion may show strong initial dissolution but lose performance during storage if moisture, temperature, or residual solvent levels are not controlled.

Nanocrystal and particle-engineered systems

Nanocrystals, co-milled particles, spray-dried dispersions, and porous-carrier systems can increase surface area and improve dissolution. These approaches can support a differentiated product but add scale-up and control challenges.

A nanocrystal product would need robust controls for:

• Particle-size distribution.
• Agglomeration.
• Residual processing solvent.
• Redispersion.
• Content uniformity.
• Ostwald ripening or particle growth.
• Dissolution after long-term storage.

For a mature generic market, the added cost is justified only if the formulation produces a material regulatory or commercial benefit.

What formulations are protected by Lipofen-related patents?

Fenofibrate has been commercially available for decades, and the active molecule is not a practical source of new composition-of-matter exclusivity. The relevant intellectual-property opportunities are formulation-specific.

Patent categories with potential commercial value

Patent category	Potential claim scope	Commercial value
Solid dispersion	Fenofibrate with a specified polymer or carrier	Moderate to high if stability and bioavailability are differentiated
Lipid formulation	Fenofibrate in a defined lipid, surfactant, or self-emulsifying system	Moderate, subject to freedom-to-operate review
Particle engineering	Nanocrystals, controlled particle size, or porous particles	Moderate
Manufacturing process	Milling, granulation, spray drying, coating, or encapsulation parameters	Moderate if difficult to design around
Method of treatment	Use in a defined patient subgroup or combination	Usually narrower and vulnerable to label-based generic entry
Capsule technology	Shell composition, moisture control, or delayed release	Low to moderate unless the technology solves a material stability issue

The Orange Book should be reviewed for current patent listings associated with Lipofen’s NDA and any relevant fenofibrate products. The existence of a formulation patent does not automatically prevent generic entry. A generic applicant can pursue a Paragraph IV certification, a section viii statement for non-patented uses, or a formulation that avoids the asserted claims (FDA, 2024a).

When does Lipofen lose exclusivity?

Lipofen has already entered the post-exclusivity generic market. Fenofibrate’s historical regulatory exclusivity and any early product patents do not provide a current barrier comparable to the exclusivity profile of a recently approved medicine.

Exclusivity position

Exclusivity issue	Lipofen assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the standard Lipofen indications
Pediatric exclusivity	No current commercial barrier identified
Active-ingredient patent	Not a current barrier for fenofibrate
Formulation patent risk	Depends on the specific proposed product and claim scope
Generic competition	Present
Biosimilar competition	Not applicable
Regulatory market access	Primarily controlled by ANDA requirements and state or payer substitution rules

The practical question is no longer whether Lipofen can exclude generic entry. The commercial question is whether a new fenofibrate product can obtain approval and win volume through lower cost, better supply, improved adherence, or a clinically meaningful formulation attribute.

What is the Orange Book status of Lipofen?

Lipofen is a small-molecule prescription drug subject to Orange Book listing and ANDA-based generic competition. The Orange Book identifies approved drug products, therapeutic-equivalence information, and relevant patent or exclusivity records. Current regulatory assessment should use the FDA’s electronic Orange Book and Drugs@FDA records rather than historical product labels alone (FDA, 2024a, 2024b).

A sponsor evaluating a Lipofen follow-on product should document:

• Current NDA holder and marketing status.
• Listed strengths and dosage forms.
• Therapeutic-equivalence codes for approved generic capsules.
• Current patent listings associated with the NDA.
• Any discontinued presentations.
• Whether a proposed product matches the reference-listed drug in strength, dosage form, route, and release characteristics.

The absence of a meaningful Orange Book patent barrier does not eliminate development risk. Fenofibrate products can still fail on dissolution, bioequivalence, impurity control, content uniformity, or manufacturing reproducibility.

Which companies are challenging Lipofen commercially?

The principal competition comes from generic fenofibrate manufacturers rather than biosimilar developers. Large generic companies and regional manufacturers have marketed fenofibrate capsules, tablets, and other formulations. Competitive intensity varies by strength, dosage form, distribution channel, and contracting strategy.

Competitive segments

Segment	Competitive basis
Standard generic capsules	Lowest manufacturing cost and broad wholesaler access
Generic tablets	Dosage-form substitution and differentiated product positioning
Brand fenofibrate products	Prescriber familiarity, contracting, and legacy market access
Authorized or private-label generics	Payer and pharmacy channel economics
New formulations	Food-effect performance, lower variability, or simplified dosing
Combination products	Convenience and treatment simplification, subject to clinical and regulatory requirements

The main commercial threat to a new Lipofen-related product is price erosion. A differentiated excipient platform must generate a clear advantage in supply reliability, bioequivalence success, manufacturing yield, or clinical use. A modest dissolution improvement alone is unlikely to support a premium price.

How strong is the patent estate for a new Lipofen formulation?

A new formulation can have a moderate patent position if claims cover a specific composition, measurable physical property, and manufacturing process. The estate is weak when claims are broad descriptions of using routine excipients with fenofibrate.

Stronger claim structures

• Defined fenofibrate-to-polymer ratios.
• Specified amorphous content or crystallinity limits.
• Particle-size or surface-area ranges linked to dissolution results.
• Dissolution thresholds in multiple media.
• Defined lipid or surfactant compositions.
• Stability claims supported by long-term data.
• Manufacturing parameters that produce a reproducible product attribute.

Weaker claim structures

• Generic use of a diluent, lubricant, or disintegrant.
• Broad lists of alternative excipients.
• Claims lacking a measurable performance limitation.
• Method-of-use claims that overlap with the approved generic label.
• Formulation claims that can be avoided by substituting a routine excipient.

For litigation planning, the sponsor should expect validity challenges based on obviousness, routine optimization, anticipation by prior fenofibrate formulations, and lack of written description. The best defense is a formulation with an unexpected performance relationship supported by comparative data.

What Paragraph IV challenges and litigation risks exist?

Generic applicants can challenge listed patents through Paragraph IV certifications. Fenofibrate’s mature market reduces the likelihood that a basic capsule patent will sustain prolonged exclusivity. Any new formulation patent would face a more direct challenge if it materially affects a high-volume product.

Main litigation issues

1. Whether the generic product practices each asserted formulation limitation.
2. Whether the patent claims are obvious in view of earlier fenofibrate formulations.
3. Whether the claimed dissolution or stability result is unexpected.
4. Whether a generic label induces infringement of a method-of-use claim.
5. Whether the brand product remains commercially marketed.
6. Whether a settlement would delay entry or permit an authorized generic.

A settlement can create value only if the patent has credible validity and infringement positions. In a low-margin generic market, litigation economics often favor early design-around strategies over extended proceedings.

What FDA regulatory pathway applies to a Lipofen excipient opportunity?

A conventional equivalent capsule would generally use the ANDA pathway. A materially different formulation may require a 505(b)(2) application if the sponsor relies on FDA findings for fenofibrate but cannot establish full sameness to the reference-listed drug.

Regulatory route comparison

Route	Best use case	Primary evidence burden
ANDA	Same dosage form, strength, route, and bioequivalence profile	Pharmaceutical equivalence, bioequivalence, CMC, labeling
505(b)(2)	New formulation, delivery system, food-effect profile, or clinical positioning	CMC plus bridging pharmacokinetic or clinical evidence
New NDA	New active ingredient or major independent clinical program	Full safety and efficacy package

FDA’s product-specific guidance and bioequivalence recommendations should determine the study design. Fenofibrate products require careful attention to fed and fasted administration, because food can affect absorption depending on formulation technology (FDA, 2024c).

What commercial opportunities exist for Lipofen excipients?

The best opportunities are formulation platforms that reduce total product cost or address a defined performance problem.

Priority opportunities

1. Low-cost bioequivalent capsule.
Use standard excipients, optimized particle size, efficient capsule filling, and robust dissolution. This is the fastest route to volume but offers limited differentiation.

2. Lower food-effect formulation.
Develop a formulation with more consistent exposure across fed and fasted conditions. This could support a 505(b)(2) strategy or strengthen product positioning if the clinical relevance is established.

3. HPMC capsule platform.
A low-moisture or vegetarian capsule may improve market access in selected channels and reduce gelatin-related procurement constraints. The change must not compromise dissolution or stability.

4. Solid-dispersion fenofibrate.
A stable polymer dispersion could support improved dissolution and a formulation patent. The commercial case depends on demonstrated superiority over standard micronized capsules.

5. Supply-chain substitution.
Dual-source excipients, direct-compression-compatible blends, and reduced processing steps can lower cost and protect against supplier disruption. This opportunity is particularly relevant for contract manufacturers and private-label generic suppliers.

6. Combination-product development.
Fenofibrate combinations with statins or other lipid-lowering agents could improve adherence, but they create greater clinical, regulatory, and patent complexity than a standalone capsule.

How does Lipofen compare with competing fenofibrate products?

Criterion	Lipofen	Generic micronized fenofibrate	Advanced fenofibrate formulation
Market maturity	Mature brand	Mature and price competitive	Emerging or niche
Patent leverage	Limited	Usually limited	Potentially meaningful
Development cost	Historical sunk cost	Low to moderate	Moderate to high
Bioequivalence risk	Reference standard	Direct comparison to reference	Higher if formulation differs materially
Excipient differentiation	Limited	Usually limited	Core value proposition
Pricing power	Low to moderate	Low	Possible if benefit is documented
Manufacturing complexity	Standard capsule	Standard capsule	Can be high
Best strategy	Brand continuity	Cost leadership	Performance or convenience

Key Takeaways

• Lipofen is a mature fenofibrate capsule product available in 50 mg and 150 mg strengths.
• Active-ingredient exclusivity is not the commercial barrier; generic competition is established.
• The most relevant excipient opportunities involve dissolution, food-effect control, powder flow, stability, and capsule-shell selection.
• Conventional excipient optimization offers the lowest regulatory risk but limited pricing power.
• Lipid systems, solid dispersions, and particle-engineered formulations offer stronger differentiation but require more extensive CMC and bioequivalence work.
• A new patent estate is strongest when it claims a defined composition, measurable performance attribute, and reproducible manufacturing process.
• The ANDA pathway is appropriate for a conventional equivalent product. A materially different delivery system may require a 505(b)(2) strategy.
• Biosimilar risk is irrelevant because fenofibrate is a small molecule.
• The most attractive commercial model is a low-cost, supply-secure generic or a formulation that demonstrates reduced food-effect variability and stable improved dissolution.

FAQs

Can fenofibrate excipients be changed without a new clinical trial?

Yes, a conventional generic can use different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and safety requirements. A materially different delivery system may require additional regulatory bridging.

Is fenofibrate suitable for a self-emulsifying drug-delivery system?

Yes. Fenofibrate’s hydrophobicity makes it a candidate for lipid-based and self-emulsifying systems. Development must control precipitation, oxidation, capsule compatibility, and fed-fast exposure differences.

Does a vegetarian HPMC capsule create meaningful market differentiation?

It can support selected procurement, patient-preference, and international-market strategies. The commercial effect is limited unless the capsule change improves stability, supply security, or target-market acceptance.

Can a new fenofibrate formulation receive 30 months of Paragraph IV stay?

A 30-month stay can arise under Hatch-Waxman procedures when an eligible patent is listed and a timely Paragraph IV certification is filed, subject to statutory requirements and litigation timing. A routine excipient change does not itself create that protection.

What is the highest-value excipient development target for fenofibrate?

A stable formulation that improves dissolution and reduces fed-fast pharmacokinetic variability has the strongest potential value. It must outperform standard micronized fenofibrate in comparative studies and support a defensible regulatory and patent position.

References

1. U.S. Food and Drug Administration. (2018). Lipofen (fenofibrate) capsules: Prescribing information. Kowa Pharmaceuticals America, Inc.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024c). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.